Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7490MR)

This product GTTS-WQ7490MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7490MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14664MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ889MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ13298MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ8020MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ1478MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ6281MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ925MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ1387MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW